Status:
COMPLETED
Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension
Lead Sponsor:
Novartis
Conditions:
Hypertension
Eligibility:
All Genders
20-75 years
Phase:
PHASE3
Brief Summary
Assessing efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension
Eligibility Criteria
Inclusion
- Age: 20 - 75 years old
- Gender: Male or female
- Status: Outpatients
- Mild to moderate essential hypertension
Exclusion
- Pregnant women, lactating mothers, women suspected of being pregnant, or women who wish to be pregnant
- Patients with msSBP \>==180 mmHg and/or msDBP \>=110 mmHg at Visit 1, 2 or 3
- Patients with or suspected of having secondary hypertension (due to aortic coarctation, primary aldosteronism, etc.)
- Patients suspected of having malignant hypertension
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2007
Estimated Enrollment :
768 Patients enrolled
Trial Details
Trial ID
NCT00344110
Start Date
June 1 2006
End Date
April 1 2007
Last Update
November 18 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
Japan, Japan